RNA — Avidity Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $2.53bn
- $1.93bn
- $9.56m
Annual cashflow statement for Avidity Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -24.7 | -44.4 | -118 | -174 | -212 |
| Depreciation | |||||
| Non-Cash Items | 7.75 | 4.53 | 17.2 | 26.5 | 26.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 19.1 | 2.33 | 5.34 | 9.82 | 64.1 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 2.49 | -37.1 | -94.8 | -136 | -119 |
| Capital Expenditures | -0.235 | -1.09 | -3.74 | -2.82 | -4.23 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -6.69 | -78.8 | -187 | -126 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.235 | -7.79 | -82.5 | -190 | -130 |
| Financing Cash Flow Items | -0.106 | -24 | -11.3 | — | 31.2 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 89.2 | 272 | 176 | 346 | 93.9 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 91.5 | 227 | -1.01 | 19.9 | -155 |